Scilex Holding Company Increase (Decrease) in Prepaid Expense
Scilex Holding Company (SCLX) reported Increase (Decrease) in Prepaid Expense of $126.25 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2022-11-04
- Scilex Holding Company increase (decrease) in prepaid expense for the quarter ending 2022-09-30 was -$130.79K.
- Scilex Holding Company increase (decrease) in prepaid expense for the quarter ending 2022-06-30 was -$135.32K, a 157.74% decline year-over-year.
- Scilex Holding Company increase (decrease) in prepaid expense for the quarter ending 2022-03-31 was $392.37K, a 13.27% increase year-over-year.
- Scilex Holding Company increase (decrease) in prepaid expense for the quarter ending 2021-12-31 was -$112.00K.
- Scilex Holding Company increase (decrease) in prepaid expense for fiscal 2021 was $4.54K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$130.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$266.11K derived: sum of 2 quarters · filed 2022-11-04 | $126.25K 10-Q · filed 2022-11-04 | $14.25K derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | -$135.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $257.04K 10-Q · filed 2022-08-12 | $145.04K derived: sum of 3 quarters · filed 2022-08-12 | $27.22K derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-03-31 | $392.37K 10-Q · filed 2022-05-16 | $280.37K derived: sum of 2 quarters · filed 2022-05-16 | $162.54K derived: sum of 3 quarters · filed 2022-11-04 | $396.90K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$229.82K derived: sum of 2 quarters · filed 2022-11-04 | $4.54K derived: sum of 3 quarters · filed 2022-11-04 | $4.54K 10-K · filed 2022-02-24 |
| 2021-09-30 | -$117.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $116.54K derived: sum of 2 quarters · filed 2022-11-04 | $116.54K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $234.36K 10-Q/A · filed 2021-08-24 | $234.36K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $346.39K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |